How does the anti-mouse CD192 antibody reveal the mechanism by which CCR2 deficiency leads to polycystic lung disease?

1. What is the immunological basis of pulmonary alveolar proteinosis and polycystic lung disease?

Pulmonary alveolar proteinosis (PAP) is a syndrome characterized by abnormal accumulation of surfactant material in the alveolar spaces, leading to progressive respiratory failure. Its etiology is diverse, including genetic defects, autoimmune factors, and environmental exposures. Hereditary PAP is primarily caused by mutations in genes encoding surfactant-associated proteins or their metabolic regulators, while the most common acquired form is mediated by autoantibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF signaling is crucial for maintaining normal alveolar macrophage function. Impairment of this signaling pathway results in macrophages' inability to effectively clear cholesterol and other lipid components from surfactant, transforming them into a foamy state and losing their clearance capacity. Recent studies have identified a childhood diffuse lung disease presenting as polycystic lung disease and recurrent infections, which is closely associated with inherited loss-of-function mutations in the chemokine receptor CCR2 (CD192). This discovery places CCR2 and its mediated monocyte recruitment process at the center of research on pulmonary homeostasis and disease mechanisms. To further explore the role of CCR2 in pulmonary immunity, highly specific mouse CD192 antibodies have become essential tools for modeling and analyzing this human disease in preclinical models.

2. How do loss-of-function mutations in CCR2 lead to human polycystic lung disease?

Clinical studies have identified multiple children with progressive polycystic lung disease and recurrent infections carrying homozygous or compound heterozygous mutations in the CCR2 gene. These mutations are located in highly conserved transmembrane domains and are predicted to be pathogenic by bioinformatics analysis. Functional validation experiments confirmed that these mutants are loss-of-function variants: when mutant CCR2 proteins were expressed in cell lines, downstream signals such as intracellular calcium flux showed no response to stimulation by the ligand CCL2. Patient-derived peripheral blood monocytes also lost the ability to migrate toward CCL2, while serum CCL2 levels were compensatorily elevated. Notably, patients exhibited normal GM-CSF signaling, interferon-γ responses, and peripheral blood cell counts. A key pathological finding is that although alveolar macrophages themselves do not express CCR2, CCR2-deficient patients showed a significant reduction in alveolar macrophage numbers. This suggests that the physiological role of CCR2 is to mediate the migration and replenishment of monocyte precursors from the bone marrow to the lung tissue. Its deficiency leads to impaired maintenance of the alveolar macrophage "pool," rather than intrinsic macrophage dysfunction. This mechanism differs from the classic GM-CSF signaling deficiency causing alveolar macrophage functional failure, revealing an independent and critical regulatory hub for alveolar macrophage quantity maintenance.

3. What is the application value of mouse CD192 antibodies in disease mechanism research?

Mouse CD192 antibodies play an irreplaceable role in modeling and analyzing CCR2-deficient lung diseases. First, these antibodies can be used to construct and study CCR2-deficient mouse models. By administering anti-CD192 antibodies to pregnant dams or injecting newborn mice, CCR2 function can be blocked to simulate the monocyte migration defect observed in human patients, allowing observation of long-term changes in alveolar macrophage development and lung pathology. Second, in mechanistic exploration, these antibodies are core tools for cell tracing and quantitative analysis. Using these antibodies for flow cytometry enables precise comparison of the number and proportion of CCR2-expressing monocyte subsets in peripheral blood, bone marrow, and lung tissues at different developmental stages between wild-type and model mice, as well as quantification of absolute alveolar macrophage numbers in the lungs. Furthermore, these antibodies can be used for blockade experiments. In wild-type mice, using blocking anti-CD192 antibodies to inhibit CCR2 function allows observation of whether control over bacterial infections (e.g., BCG) is reduced and whether early signs of surfactant clearance impairment appear, thereby validating the causal relationship between CCR2 deficiency and infection susceptibility or PAP-like pathology in vivo.

4. Why does alveolar macrophage deficiency lead to polycystic lung disease and infections?

Alveolar macrophages are the "scavengers" and first-line defenders of the lungs, responsible for clearing apoptotic cells, inhaled particles, and excess surfactant, while also playing a vital role in anti-infection immunity. CCR2 deficiency prevents normal recruitment of monocytes to the lungs, resulting in a persistent shortage of alveolar macrophages. This absolute reduction in numbers first weakens the lung's daily clearance capacity for surfactant and its metabolites (e.g., cholesterol), leading to gradual accumulation of these substances in the alveolar spaces. Long-term lipid deposition may trigger local inflammatory responses and tissue remodeling, eventually forming cyst-like structures visible on imaging as polycystic lung disease. Second, the shortage of alveolar macrophages directly weakens the innate immune defense barrier in the lungs. Patients exhibit recurrent infections with various pathogens, including BCG, directly linked to the "depleted兵力" of pulmonary innate immune cells. Thus, CCR2 deficiency affects the "source" of alveolar macrophages rather than their intrinsic "quality," simultaneously causing both PAP-like pathology and immunodeficiency.

5. Which manufacturers provide mouse CD192 antibodies?

Hangzhou Start Biotech Co., Ltd. has independently developed the "Rat Anti-Mouse CD192 Antibody (S-R731)" (Catalog No.: S0B5295), a high-specificity, high-affinity, and highly stable chemokine receptor detection antibody. This product uses high-quality rat monoclonal antibodies to efficiently and specifically bind mouse CD192 (CCR2) molecules. It performs excellently in applications such as flow cytometry (FACS), immunohistochemistry (IHC), and immunofluorescence (IF), making it a key tool for studying monocyte/macrophage migration, inflammatory responses, and various chronic disease models.

Professional Technical Support: We provide detailed technical parameters for this product, including recommended concentrations, applicable sample types (e.g., peripheral blood, spleen, bone marrow, inflamed or tumor tissues), and suggestions for multicolor flow cytometry panel combinations. Our technical team offers expert consultation.

Hangzhou Start Biotech Co., Ltd. is committed to providing high-performance, high-quality antibody reagents for mouse model immunology research. For more information about the "Rat Anti-Mouse CD192 Antibody" (Catalog No. S0B5295), validation data, or sample requests, please feel free to contact us.

Product Information

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.